CXCR4 and myocardial infarction: A phase II trial evaluated the role of POL6326 (a CXCR4 antagonist) as a stem-cell mobilizer and whether it can improve heart function after myocardial infarction (NCT01905475; EudraCT 2012- 003229-91).